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Summary The spontaneous expression of HLA class I and class II molecules in two human breast carcinoma
cell lines (MCF7, T47D) and their modulation during epidermal growth factor treatment are reported.
Transcription was analysed by Northern blot and hybridisation with HLA class II and class I cDNA specific
probes. The expression of cell surface determinants was examined by internal protein labelling with 35s-
methionine, immunoprecipitation with monoclonal antibodies specific for HLA class I or class II, followed by
isolation of the immune complex on protein A-Sepharose; at least a quantification of glycoproteins was
performed by chromatofocusing. Glycoprotein quantification showed a significant increase of HLA class I and
class II (DR) antigen expression after stimulation by epidermal growth factor (0.02 ggml-') in the two cell
lines, when compared with untreated cell controls. However, with epidermal growth factor treatment of MCF7
and T47D cells, low increases in the amounts of HLA class I and class II RNA were obtained. These
differences between expressed antigens and correspondent RNA amounts would be explained by the fact that
EGF in these two cell lines acts more in post-transcription for HLA class I and class II antigens.
HLA class I and class II molecules regulate the overall
immune response by mediating interactions among various
immunocompetent cells. Class I molecules serve as restriction
elements for T-cell-mediated cytotoxicity (Zinkernagel, 1979)
and class II molecules are required for the presentation of the
antigen to the helper T cell (Benaceraf, 1988). In normal
tissues, HLA class I antigens (Ags) are expressed by most
nucleated cells (Ploegh et al., 1981), while HLA class II have
a more restricted pattern of expression. They were first
reported to be associated with the hematopoietic and
immune lineage and, more recently, have been described in a
variety of normal cells, either resting or activated (Radka et
al., 1986).
In tumoral tissues, HLA class I and class II expression is
extremely variable, but of importance. The presence of HLA
class I molecules is inversely correlated with the degree of
tumorigenicity in some animal models (Pfizenmaier et al.,
1985), and HLA class II are known to play a role in the
interaction between the host's immune system and tumour
cells (Ferrone, 1982).
In the breast gland, while normal resting mammary tissue
expresses class I but not class II antigens, these class II are
found on glandular cells during lactation, where they are
expressed on the milk fat globule membranes (Newman et
al., 1980). Class II may be induced by exogenous administra-
tion of prolactin, suggesting a hormonal regulation of Ia
antigens in the mammary gland and a possible correlation
with the differentiation process (Klareskog et al., 1980; Ber-
nard et al., 1986a, 1990).
In addition, other studies have reported the expression of
HLA class II Ags on some malignant tissues of non-
lymphoid origin as melanoma (Houghton et al., 1982);
adenocarcinoma from the stomach, the colon, the sigmoidal
anse, the rectum, the spleen, the lung and the ovary; thymic
carcinoma, prostate carcinoma, breast medullary carcinoma,
bladder carcinoma, cystic astrocytoma, ganglioneuroblas-
toma, glioblastoma, and meningioma (Howe et al., 1981;
Natali et al., 1981; Ng et al., 1981).
Epidermal growth factor (EGF) has been shown to
stimulate in vitro growth of epithelial cells derived both from
normal breast and mammary carcinomas and that EGF may
play a role in regulating growth of breast cancer cells in vivo
(Fitzpatrick et al., 1984).
In this work, we define and analyse cell-surface expression
and RNA transcripts of class I and class II before and after
EGF treatment to determine whether this response was
variable in different tumour cell lines from the same origin.
Materials and methods
Cell lines and cultures
Two human breast carcinoma cell lines have been studied.
They were derived from metastatic breast carcinomas: MCF7
(Soule et al., 1973) and T47D (Keydar et al., 1979). These
cell lines were cultured in closed plastic T75 flasks (Corning,
New York 14830), in growth medium composed of RPMI
1640 (Gibco Europe Ltd, Renfrewshire, Scotland), buffered
with 2 gl-' sodium bicarbonate, supplemented with 10%
foetal calf serum, 2 mM L-glutamine, 50 UI ml-' penicillin
and 50 fig ml- ' streptomycin. For MCF7 cell line, 0.04 U
ml-' insulin was added to growth medium. Cells were grown
in a humidified incubator with 5% CO2 at 37°C. Cultures
were refed every 2 to 3 days. Culturing (after I week growth)
involved trypsin digestion (7.5 mg in 3 ml-' PBS for a flask),
to obtain monocellular suspensions followed by the plating
of 3 x 106 cells/flask. Cultures were confluent after 1 week
(approximately 10 x 106 cells/flask).
In assays of the EGF effects on class I and class II HLA
Ag expression, cells were grown for one week (with a
refeeding to day 3). Immediately after cell passage, 30 ml of
medium (supplemented as described above) were added with
EGF to a final concentration of 0.02 jig ml-) of culture.
In parallel, control cells without any treatment were refed
and collected at the same time with EFG-treated cells.
Raji cell line was grown in closed plastic T75 flasks (Corn-
ing, New-York 14830) in RPMI 1640 supplemented with
10% foetal calf serum (Pulvertaft, 1965) in suspension under
the concentration of 0.5 x 106 cells ml-'.
Reagents
Epidermal growth factor (EGF) (Collaborative Research
Incorporated, Bedford MA 01730) with receptor grade from
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mouse submaxillary glands was added to culture medium.
The monoclonal antibody (MoAb) anti-HLA class II was
an anti-human DR framework (anti-OKIa) and was obtained
from the Ortho Pharmaceutical Corp., Raritan, NJ, at the
concentration of 2 mg ml-'. The MoAb anti-HLA class I was
specific to human P2-microglobulin (HLA-ABC-m2) and was
obtained from Silenus, Victoria, 3122 Australia.
Probes
HLA class II locus specific probes were derived from cDNA
clones: DRx (Wake et al., 1982) (500 bp), DQa (Auffray et
al., 1982) (500 bp). The inserts were radiolabelled by the
random priming technique (Boehringer Mannheim). HLA
class I (B) specific probe was derived from a cDNA clone,
pAS3-6 (Coppin et al., 1985) (6.5 Kb). This probe was
radiolabelled by Nick translation technique (Amersham).
RNA extraction
Direct RNA extraction was performed by homogenisation of
starting material in 7 ml cells of 0.01% SDS, 6M urea and
3 M LiCl for 107 cells at full speed for 4 min with an ultratur-
rax. The homogenate was kept overnight at 4°C in ice. The
RNA was pelleted by centrifugation at 4°C for 30 min at
8,000 rpm (Sorvall RC 5C). The DNA in solution was
removed. The collected RNA was dissolved in sterilised bidis-
tillated water. Then the homogenate was treated for 5 min at
65°C, gently vortexed, and sodium acetate pH 5 was added to
0.1 M final concentration. Then, RNA was separated from
proteins by two phenol extractions and precipitated with
2.5 vol ethanol at -20°C. The RNA purification was im-
proved with a second ethanol precipitation with 0.3 M
sodium acetate pH 5 (Auffray, 1980).
Northern blot analysis ofRNAs
Equal amounts of total RNAs (25jg) were denatured at
65°C for 5 min and quickly cooled to room temperature, then
electrophoresed on a 1% agarose gel containing 3% for-
maldehyde in buffer pH 8.3 containing 0.4 M boric acid and
0.2 M EDTA. They were then transferred onto a gene screen
membrane (Hybond N+, Amersham) using 20 x SSC
buffer. After transfer, RNAs were fixed to the membrane by
a brief alkali treatment. Northern blots were pre-hybridised
at 42°C for 4 h in a solution containing 4 x SSC buffer,
0.005 M NaPO4 buffer pH 6.5, 0.2% SDS, denatured Salmon
sperm DNA (10 gml-'), 50% formamide, 0.05% Denhardt's
solution. Hybridisation was performed overnight at 42°C in
the same solution with 30% dextran sulfate and 32P-labelled
probe. Membranes were washed three times in 2 x SSC and
0.5% SDS for 15 min. at 42°C, then three times in 0.5 x SSC
and 0.1% SDS for 15 min at 42°C. The 32P-DNA bound to
the filters was visualised by autoradiography at - 80°C using
Hyperfilm TMMP (Amersham) and intensifying screens
(Dupont, Wilmington, DE). All intensity bands were quanti-
fied and related to their radioactivity with a computerised
densitometer Allen Bradley Servovision (Rockwell Int. Cy.),
using the Expert PVS 20805 software programme.
Radiolabelling ofcells
Internal labelling with 35S-methionine was performed in flask
when culture was at confluence, corresponding to a density
of approximately 107 cells/flask. Before labelling, the medium
was removed and each flask received 3 ml of the sterile
culture medium described above, with 100tiCi 35S-methionine
(366 mCi/ mM; Amersham International plc, England). The
mixture was incubated at 37°C in a 5% CO2 incubator for
5-6 h. At the end of this time, label incorporaton was stop-
ped by adding 10 ml cold PBS. The cells were then gently
washed in PBS at 4°C (Bernard et al., 1986b).
Preparation ofNonidet P-40 extracts
Washed 35S-methionine cells were solubilised in the culture
flask by 3 ml of0.5% Nonidet P-40 (NP-40; Sigma, Chemical
Company, St-Louis, NO, USA) in Tris-buffered saline
(150 mMNaCl, 50mM Tris, 0.02% NaN3pH 7) and
incubated for 15 min at 4°C. The insoluble material was
removed by centrifugation at 30,000 g for 30 min. The ext-
racts collected were used immediately or stored at - 80°C.
Isolation ofglycoproteins by affinity chromatography
The NP-40 cell lysates were precleared by affinity chromatog-
raphy on Lentil-Lectin Sepharose 4B to remove labelled pro-
teins. Labelled glycoproteins bound to Lentil-Lectin gel were
eluted with 2% a-Methyl Mannoside (Sigma) in PBS.
Purification ofHLA Ags onprotein A-Sepharose CL-4B
Radiolabelled glycoproteins eluted from Lentil-lectin-
Sepharose 4B were pooled and concentrated to a volume of
1 ml by ultrafiltration (Immersible CX 10, Millipore Cor-
poration, Bedford, MA, USA). Class II or class I HLA Ags
were then immunoprecipitated specifically by a 30 min
incubation time at 370C with 20jil anti-class II or class I
HLA MoAbs. The obtained immunoprecipitate was isolated
from Protein A-Sepharose CL-4B (Pharmacia Fine Chemical,
Uppsala, Sweden) after elution with 0.025 M citrate buffer
pH 2.6.
Quantification ofHLA Ags by chromatofocusing
Then, quantification of radiolabelled HLA Ags was perform-
ed by chromatofocusing on PBE 9-4 gel column (Pharmacia)
as follows. The fractions containing the immune complex
eluted from Protein A-Sepharose were dialysed against
0.025 M ethanolamine buffer, pH 9.4 and then were poured
over the top of the column (1 x 30 cm), which had been
equilibrated with three column volumes of 0.025 M ethano-
lamine, ph 9.4. Elution was carried out with Polybuffer 9-6,
pH 6 (Pharmacia) at 10ml h'. Two ml fractions were col-
lected with an automatic collector (Gilson). The radioactivity of each fraction was measured with a dual-channel auto-
gamma spectrometer. When the 35S-specific activity of glyco-
proteins eluted from Lentil-Lectin-Sepharose 4B is known,
the amount of 35S-labelled glycoproteins which bind speci- fically to the MoAb can be deduced (Bernard et al., 1984a,b,
1985, 1990).
Statistical analysis
Differences in quantification by affinity chromatographies
and following chromatofocusing between treated cells with
EGF and untreated cells were assessed by student's t-test.
Results
RNA studies
Results are shown in Figure 1. HLA cDNA probe used for
class I studies detected the classical RNA band of 1.7 Kb in
T47D and MCF7. After treatment with EGF (0.02figml-' culture medium), the 1.7Kb band was increased 3-fold in MCF7 cells and no difference was seen between T47D control
cells and correspondent EGF-stimulated cells.
HLA cDNA probe used for class II DRa showed the
expected RNA band at 1.5 Kb in MCF7 cells, which was increased 3-fold in intensity after cell stimulation with EGF. Conversely T47D untreated cells showed a very low amount of class II DRax RNA which increased not significantly after EGF stimulation. With HLA class II DQa probe, no band
was detected. Then a weak induction of DQax was obtained with EGF stimulation in MCF7 cells, so that no DQoc band
could be detected in T47D controls nor in T47D treated with EGF. For RNA Northern blots with HLA class II and class90 D.J. BERNARD et al.
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Figure I Northern blot analysis of HLA class I and HLA class II RNA in two human breast adenocarcinoma cell lines: MCF7
and T47D. Total RNA from EGF-treated or untreated cells were electrophoresed, transferred onto membrane and hybridised with
the HLA class I and class II chain specific cDNA probes. Raji cell line was used as control for HLA class I and class II RNA
bands. Under each point, the value corresponds to the radioactivity band computerised in a densitometer Allen Bradley Servovision
using the Expert PVS 20805 Software.
I, Raji cell line was used as control because they are known
to express class I and class II Ags.
In contrast to these results, levels ofP-actin RNA were not
affected by EGF treatment (data not presented).
Modulation ofHLA class I and class II antigen expression by
EGF
After the internal cell labelling with 35S-methionine, the
specific immunoprecipitation of HLA class I and class II
(DR) Ags with correspondent MoAbs, the quantification of
Ags after affinity chromatographies and chromatofocusing
showed a significant increase after EGF treatment in the
expression of the HLA class I and class II (DR) Ags in both
studied breast tumor cell lines (MCF7 and T47D), when
compared with the correspondent control group (untreated
cells). Results are expressed in Table I.
With our quantification method, we found in MCF7 cell
line that the expression of HLA class I Ags increased 7-fold
and HLA class II (DR) Ags 10-fold when stimulation with
EGF (0.02jiml-' culture medium) was performed. Mean-
while, in T47D cell line, HLA class I Ags increased 3-fold,
and HLA class II (DR) Ags increased 4-fold after EGF
stimulation (0.02 fLg ml-' culture medium).
Discussion
This work was undertaken to determine qualitative and
quantitative changes induced in HLA class I and class II
molecules by EGF in two human breast adenocarcinoma cell
lines: MCF7 and T47D. To this purpose, qualitative changes
in HLA class I and class II RNA were realised with North-
ern blotting and quantification of Ags class I and class II
(DR) was performed with MoAb-binding studies.
In this study, we demonstrated that EGF increased only
class I RNA expression in a breast adenocarcinoma cell line,
MCF7, but the rates remained slower than in lymphoblastoid
cells (Raji). Moreover, no change was obtained for RNA
class I in T47D cells after EGF stimulation. Besides, we
found an increase in class I surface-antigen expression in
T47D cell line and in MCF7 cells but it was smaller in T47D
cell line.
For class II MHC Ags which showed a limited tissue
distribution in vivo and are involved in the presentation of
Ag to T-helper cells; EGF significantly increased the class II
DRa RNA and the expression of surface DR Ags in MCF7
cells. For T47D cells, after EGF stimulation, the increased
change for DRa RNA and DR Ag expression are weaker
than in MCF7 cells.
CLASS II MCF7 Raji MCF7 +
Control EGF
*DRa
*DQoE
-1.5 Kb
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Table I Effects ofEGF, measured after affinity chromatographies and following chromatofocusing, on expression ofHLA class I and
class II antigens by two breast tumour cell lines: MCF7 and T47D
Breast tumour cell lines MCF7 T47D
Ags assayedby chromatofocusing class la class Il class I class II
Glycoproteinsc 286,500± 89,000 242,000+83,000 307,000± 90,300 213,000+ 24,000
(3)e (7) (4) (3)
Untreated cells Immune complexd 5,300±2,200 4,500+2,000 10,200±3,050 9,200+ 1,800
Amounts of Ags after (1.84±0.76) % (1.86±0.82) % (3.32± 1.11) % (4.32±0.92) %
chromatofocusing
Glycoproteins 766,000± 136,000g 1109,000+667,500h 621,000± 120,000 499,000± 87,000h
Cells treated (3) (4) (3) (3)
with EGFf Immune complex 38,000±6,700' 42,000+ 18,900i 34,200±9,000i 34,200+ 10,000i
Amount of Ags after (4.9±0.87) % (3.79± 1.71) % (5.51± 1.45) % (6.84±2.02) %
chromatofocusingk
aThe MoAb anti-HLA class I was specific to human P2-microglobulin. "The MoAb anti-HLA class II was an anti-human DR
framework. cSpecific activity of whole glycoprotein purified from Lentil-Lectin Sepharose 4B. This value is expressed in d.p.m. and
corresponded to 10' cells. dThe immune complex corresponded to the amount of glycoprotein antigens that bound specifically to the
correspondent MoAb. Thisvaluewasobtained from chromatofocusing andwasexpressed ind.p.m. andcalculated to 1O'cells. eNumber
ofdeterminationswith EGF(0.02 ytgml-') to culture medium. g,h,iiSignificantly different fromcorrespondentcontrol group(P<0.001).
kThe amount of Ags obtained by chromatofocusing was expressed in %, meaning the ratio, amount of glycoproteins which bind
specifically to the MoAb/specific activity of whole glycoproteins purified on Lentil-Lectin Sepharose 4B (values were expressed as
means±s.e.m.).
A different type of response in the transcription of DQot
locus after EGF treatment was observed in the two cell lines.
DQa RNA was induced in MCF7 cells while no DQax RNA
band could be detected in T47D cells in Northern blotting.
As in MCF7 and T47D cells, the high levels of class I and
class II (DR) Ags measured by binding MoAbs contrasted
with the low levels of DRa and class I RNA transcripts. This
may account with the fact that EGF in these cells modulate
HLA class II or I in the post-transcription.
Moreover, this discordance in RNA between the two loci
(DR and DQ) and the different cell lines may reflect a
locus-independant regulation and a different degree of differ-
entiation. It may also imply other transcriptional regulatory
factors (De Preval, 1988; Yunis et al., 1989).
EGF appeared to act as an inducer of HLA class I, HLA
class II in breast adenocarcinomas. The functional signi-
ficance of increased class II Ag expression in neoplastic
tissues may play a role in antigen presentation.
Furthermore, increased expression of EGF receptor has
been found in a variety of tumours: glioblastomas, squa-
mous-cell carcinomas (Merlino et al., 1984; Ullrich et al.,
1984; Libermann et al., 1985; Yamamoto et al., 1986),
human breast cancer cell lines and in membrane prepared
from breast cancer biopsies (Fitzpatrick et al., 1982, 1984;
Lebeau & Goubin, 1987).
On the other hand, associations between HLA class I
molecules and cell-surface receptors for various growth fac-
tors and hormones have been well documented (Haliotis et
al., 1990). Receptors thought to associate with class I
molecules are numerous but include epidermal growth factor.
Shreiber et al. (1984) had used a monoclonal antibody to
human class I antigens, HLA-A, B, C, to probe the interac-
tion of these antigens with the receptor for EGF in intact
cells. They showed that in two different cell types, human
tumour cells and normal human fibroblasts, the binding of
antibody to HLA antigens alters the display of EGF recep-
tors, while binding of EGF to its receptors affects the binding
of antibody to HLA.
In many previous publications, we have already reported
the hormonal modulation of HLA class II molecules for
neoplastic non-hematopoietic-derived tissues such as N-
nitroso-N-methylurea (NMU)-induced rat mammary carcin-
oma and MCF7 breast tumour cell line. An increase in the
expression of HLA class II antigens was observed after treat-
ment with prolactin, and a decrease was seen after treatment
with 2a-bromoergocryptine (an inhibitor of pituitary prol-
actin secretion). These treatments did not modify the total
prolactin receptor amounts in NMU-induced rat mammary
tumours (Bernard et al., 1986b). Effectiveness of prolactin on
the induction of HLA class II antigens was also demon-
strated in vitro for the human breast cancer cell line MCF7
(Bernard et al., 1986a) which possesses specific prolactin
receptors with a higher density than normal human mam-
mary cell lines (Shiu et al., 1979).
Moreover, we had investigated the negative effects of cyc-
losporine A (an immunosuppressive agent) on the expression
of HLA class II antigens, resulting from a competition
between cyclosporine and prolactin to the prolactin recep-
tors. A significant decrease was obtained in HLA class II
antigen expression by NMU-induced mammary tumours of
animals treated with cyclosporine A because cyclosporine A
acts as an antagonist to prolactin receptors in such hormone-
dependent mammary cancer (Bernard et al., 1990). Further
evidence of antagonism of prolactin binding to prolactin
receptors by cyclosporine A was demonstrated on a breast
tumour cell line (MCF7) by measuring the decreased specific
'25I-labelled prolactin-binding to prolactin receptors with in-
creasing concentrations of cyclosporine A (Bernard et al.,
1991).
At the same time, we had also studied the ovarian hor-
mone modulation of HLA class II antigens expressed by the
NMU-induced rat mammary tumour cells. The administra-
tion of 17p-estradiol was highly effective in decreasing the
expression of HLA class II antigens and conversely pro-
gesterone was without any effect on expression of HLA class
II antigen expression when compared with the rat control
group receiving only NMU (Bernard et al., 1989).
So, a few substances do indeed influence the expression of
HLA class II antigens in mammary cancers. And new
evidence for a variety of disciplines supports the notion that
the MHC complex influences nonimmunological functions in
the regulation of cell proliferation and the malignant pheno-
type.
Further studies are now required to define better the regul-
ation of HLA molecules in cancer surveillance.
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